Evidence map›Paper›PMID 32123386›Full record

ArticleNature medicine2020

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

Elisabeth H Thijssen, Renaud La Joie, Amy Wolf, Amelia Strom, Ping Wang, Leonardo Iaccarino, Viktoriya Bourakova, Yann Cobigo, Hilary Heuer, Salvatore Spina and 22 more

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 458 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
458citing papers in PubMed, 9 pooled it
63.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02372773 completednot on this map

Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects

TypeobservationalSponsorMayo ClinicRan2015 to 2020Enrolled398ConditionsFamilial Frontotemporal Dementia
NCT06529744 recruitingnot on this mapstarted 2023, after this paper: background citation

Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

Typeobservational_patient_registrySponsorUniversity Health Network, TorontoRan2023 to 2027Enrolled500ConditionsDementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia
3 · Its place in the literature

Who cites it

458 citing papers in PubMed, 9 syntheses or guidelines pooled it, 782 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Review
  17. Distinct ocular microvascular alterations in Alzheimer's disease and cerebral small vessel disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  18. Review
  19. Article
  20. Article

398 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 5 institutions in 4 countries.

Elisabeth H ThijssenMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Renaud La JoieMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2581-8100
Amy WolfMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Amelia StromMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Ping WangMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Leonardo IaccarinoMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Viktoriya BourakovaMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Yann CobigoMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Hilary HeuerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Salvatore SpinaMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Lawren VandeVredeMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8304-6711
Xiyun ChaiEli Lilly and Company, Indianapolis, IN, USA.
Nicholas K ProctorEli Lilly and Company, Indianapolis, IN, USA.
David C AireyEli Lilly and Company, Indianapolis, IN, USA.
Sergey ShcherbininEli Lilly and Company, Indianapolis, IN, USA.
Cynthia Duggan EvansEli Lilly and Company, Indianapolis, IN, USA.
John R SimsEli Lilly and Company, Indianapolis, IN, USA.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kaj BlennowInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Anna M KarydasMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Joel H KramerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Lea T GrinbergMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
William W SeeleyMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Howie RosenMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Bruce L MillerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Jeffrey L DageEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-2192-1699
Julio C RojasMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Adam L BoxerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA. adam.boxer@ucsf.edu.ORCID http://orcid.org/0000-0002-1215-5064
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators
University of California, San Francisco · USEli Lilly (United States) · USSahlgrenska University Hospital · SEAmsterdam Neuroscience · NLMayo Clinic in Arizona · US

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Serggio Carlo Lanata · 2019 to 2026
$36.9M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
Multidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasT32AG023481 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRUCE L MILLER, HOWARD J ROSEN · 2005 to 2026
$7.4M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
NIA NIH HHS K08 AG052648NIA NIH HHS K23 AG059888NIA NIH HHS K24 AG045333NIA NIH HHS K24 AG053435NIA NIH HHS P01 AG019724NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG045611NIA NIH HHS R01 AG062268NIA NIH HHS RF1 AG050967NIA NIH HHS T32 AG023481NIA NIH HHS U01 AG045390NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NIMH NIH HHS R01 MH120794NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid β positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid β-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by

Indexed as

AgedAlzheimer DiseaseAmyloidAmyloid beta-PeptidesBiomarkersCognitionFemaleFrontotemporal Lobar DegenerationGray MatterHeterozygoteHumansMaleMiddle AgedMutationNeurofilament ProteinsPhosphorylationAmyloidAmyloid beta-PeptidesBiomarkersneurofilament protein LNeurofilament Proteinstau Proteins

Identifiers

PMID32123386
PMCPMC7101073
OpenAlexW3009833354

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.